Brief: Journey Medical Achieves 50% Enrollment In Phase 3 Trials Of Papulopustular Rosacea Treatment

Journey Medical

30/08/2022 14:25

Aug 30 (Reuters) - Journey Medical Corp  DERM.O :
    * JOURNEY MEDICAL CORP ANNOUNCES 50% ENROLLMENT MILESTONE
ACHIEVED
IN PHASE 3 CLINICAL TRIALS EVALUATING DFD-29 FOR TREATMENT OF
PAPULOPUSTULAR ROSACEA
    * JOURNEY MEDICAL CORP - CO TO ANNOUNCE TOPLINE DATA IN
FIRST HALF
OF 2023, WITH A NEW DRUG APPLICATION SUBSEQUENTLY EXPECTED IN
SECOND HALF OF 2023
    * JOURNEY MEDICAL CORP - AFTER APPROVAL, WE ANTICIPATE
DFD-29
ACHIEVING PEAK ANNUAL NET SALES IN EXCESS OF $100 MILLION
    * JOURNEY MEDICAL CORP - NO MAJOR SAFETY ISSUES HAVE BEEN
REPORTED, AND NO DRUG-RELATED SERIOUS ADVERSE EVENTS HAVE BEEN
OBSERVED

Source text for Eikon:  ID:nGNX906Ncc 
Further company coverage:  DERM.O 

 ((Reuters.Briefs@thomsonreuters.com;))